Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update
NORCROSS, Ga., May 15, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:…
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
- The late-breaking oral presentation at SGO 2025 highlights consistent response rates…
Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial
December 12, 2024 06:00 ET | Source: Keros Therapeutics, Inc. Keros will…